ArticleEuropean radiology2025
Whole-tumor histogram analysis of synthetic MRI for the differentiation of benign and malignant soft-tissue tumors: a preliminary study.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpretable habitat radiomics model based on multi-sequence MRI for risk prediction of metachronous liver metastasis in rectal cancer: a multicenter study.Japanese journal of radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesTo determine the diagnostic potential of histogram features derived from synthetic magnetic resonance imaging (SyMRI) for the differentiation of benign and malignant soft-tissue tumors (STTs). MATERIALS AND
methodsSeventy-two patients with STTs of the extremities or trunk (29 benign, 43 malignant) were prospectively enrolled. Quantitative histogram features, extracted from T1, T2, and proton density (PD) images, were obtained by delineating the three-dimensional volume of interest (VOI). Patients were divided into a benign group and a malignant group according to their pathological results. Logistic regression was used to construct diagnostic models. Receiver operating characteristic (ROC) analysis was performed to assess diagnostic performance.
resultsSeveral histogram features derived from SyMRI, such as PD_Energy, T1_Skewness, and T2_Kurtosis, were significantly elevated in patients with malignant STTs (p < 0.05). All the models constructed on the basis of SyMRI histogram features performed comparably to or better than the Clinical_Model (a model based on conventional MRI features). The Combined_Model (a model integrating histogram features from the PD, T1, and T2 maps) has the highest AUC (0.946).
conclusionWhole-tumor histogram analysis via SyMRI can distinguish benign from malignant STTs well. The Combined model, incorporating features from the PD, T1, and T2 models, is effective. Future efforts should focus on external validation across multiple institutions and prospective prognostic validation studies. KEY POINTS: Question Differentiating between benign and malignant STTs is crucial for effective treatment, but current imaging methods struggle to reliably distinguish these tumor types. Findings Whole-tumor histogram analysis using SyMRI identified significant differences in quantitative features between benign and malignant STTs with high diagnostic accuracy. Clinical relevance This non-invasive imaging approach enhances diagnostic precision, reducing the need for biopsies and assisting clinicians in developing tailored treatment strategies for soft-tissue tumor patients.
Indexed as
Identifiers
40569439What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.